JOHNSON & JOHNSON — Director's Dealing 2004

Apr 30, 2004

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BARRIER THERAPEUTICS INC (BTRX)
CIK: 0001173657
Period of Report: 2004-04-28

Reporting Person: JOHNSON & JOHNSON (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2004-04-28	Common Stock	C	4448076	—	Acquired	4448076	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2004-04-28	Series A Convertible Preferred Stock	$	C	8333333	Disposed		Common Stock ()	Indirect
2004-04-28	Series B Convertible Preferred Stock	$	C	50000	Disposed		Common Stock ()	Indirect
2004-04-28	Series C Convertible Preferred Stock	$	C	512820	Disposed		Common Stock ()	Indirect

Footnotes

F1: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiaries of the Reporting Person: Johnson & Johnson Consumer Companies, Inc. (1,016,666 shares of Common Stock); Janssen Pharmaceutica Products, L.P. (3,150,000 shares Common Stock); Johnson & Johnson Development Corporation (281,410 shares Common Stock).

F2: Automatic conversion of each share of Series A Convertible Preferred Stock, owned by Johnson & Johnson Consumer Companies, Inc. and Janssen Pharmaceutica Products, L.P., into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering.

F3: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiaries of the Reporting Person: Johnson & Johnson Consumer Companies, Inc.; Janssen Pharmaceutica Products, L.P.

F4: Automatic conversion of each share of Series B Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation , into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering.

F5: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiary of the Reporting Person: Johnson & Johnson Development Corporation.

F6: Automatic conversion of each share of Series C Convertible Preferred Stock, owned by Johnson & Johnson Development Corporation, into .5 shares of Common Stock upon the effectiveness of the Issuer's initial public offering.

F7: The securities reported as being indirectly beneficially owned by the Reporting Person are directly beneficially owned by the following subsidiary of the Reporting Person: Johnson & Johnson Development Corporation.